Growth hormone therapy for syndromic disorders

Growth Hormone and Its Disorders

Growth hormone and its disorders.

Growth hormone (GH) is synthesised and secreted by the somatotroph cells of the anterior lobe of the pituitary gland. Its actions involve multiple organs and systems, affecting postnatal longitudinal growth as well as protein, lipid, and carbohydrate metabolism. GH hypersecretion results in gigantism or acromegaly, a condition associated with significant morbidity and mortality, while GH defici...

Growth hormone therapy for protein catabolism.

GH and IGF-I have shown remarkable consistency of effect in a wide range of catabolic conditions. Doses of around 10 IU/m2/day of GH and 80 micrograms/kg/day of IGF-I over short periods of time can improve net protein synthesis and preserve lean body mass. Most studies have reported metabolic endpoints, but favorable clinical effects have included decreased hospital stay and mortality in burns,...

Optimization of growth hormone therapy in growth hormone deficient children.

Successful treatment with human growth hormone (hGH) was initially reported by Raben in 19581. Although itis well established that pituitary derived or biosynthetic hGH increases the growth rate in growth hormone deficient children, many patients that were treated in the early days have not reached their target height, or attained adult height below the third percentile of population standards ...

Pituitary Disorders Pediatric Growth Hormone Deficiency

Optimal therapy of growth disorders depends on accurate diagnosis and clear goals for therapy. Understanding normal patterns of growth hormone (GH) and insulin-like growth factor secretion are necessary to appreciate the different hormone pattern induced by therapy. Finally, monitoring efficacy and safety, identifying interfering factors, and adjusting doses, are all part of optimizing GH thera...